Skip to content
Poster

Tirzepatide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH-HCC with advanced fibrosis

Background & aim:

The glucagon-like peptide-1 receptor (GLP1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist tirzepatide is currently approved for the treatment of obesity and type 2 diabetes.

In a recent phase 2b trial (SYNERGY-NASH) in patients with metabolic-dysfunction associated steatohepatitis (MASH), tirzepatide showed a significant effect on MASH resolution without worsening fibrosis after 52 weeks (Loomba et al., NEJM, 2024).

The present study aimed to evaluate therapeutic efficacy of tirzepatide on clinically relevant metabolic, biochemical and histopathological outcomes in addition to tumor burden in the GAN diet-induced obese (DIO) mouse model of MASH with advanced fibrosis and hepatocellular carcinoma (HCC).

Subjects
GAN DIO-MASH-HCC mouseMouseBody weightBlood biochemistryMetabolic dysfunction-associated steatohepatitisGIP receptorGLP-1 receptorHistopathology scoreImage analysisImmunohistochemistry (IHC)Liver biopsyLiver morphometryTirzepatide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top